EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing’s Syndrome

Rosario Pivonello, Chiara Simeoli, Nicola Di Paola, Angelica Larocca, Erminio Massimo Crescenzo, Annamaria Colao

touchREVIEWS in Endocrinology · 2024 · 20 (1)

DOI: 10.17925/ee.2024.20.1.8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift touchREVIEWS in Endocrinology, 2024. Verfasst von Rosario Pivonello und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina Clinicae Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologiae Nutrizione, Università "Federico II" di Napoli, Nap…. Die Arbeit wurde bisher 20-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osilodrostat is a novel potent oral steroidogenesis inhibitor with a non-steroidal chemical structure, recently approved for the treatment of adult patients with endogenous Cushing's syndrome, and Cushing's disease not cured bytab pituitary surgery or in whom pituitary surgery is not an option. Osilodrostat has been evaluated in different multicentre phase II and III clinical studies, and has shown to have notable effects, such as significant reductions in cortisol secretion, associated with significant improvement in body weight, blood pressure, glucose metabolism, lipid profile, psychological status and quality of life. The favourable safety profile, combined with the relevant efficacy, could make osilodrostat suitable as medical treatment in several phases of the Cushing's syndrome treatment journey: before surgery, as preoperative treatment, or instead of surgery, in cases where surgery is not an option or refused, as first-line treatment; after surgery, in cases of persistent or recurrent disease, as second-line treatment; after second surgery or radiotherapy following pituitary surgery as bridging treatment waiting for the definitive disease control, as third-line treatment. Further real-world clinical experience data are needed to confirm the current knowledge.

Schlagwörter

Stichwörter der Autor:innen

Cushing's diseaseCushing's syndromemedical treatmentosilodrostatsteroidogenesis inhibitor

Autor:innen und Institutionen

  • Dipartimento di Medicina Clinicae Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologiae Nutrizione, Università "Federico II" di Napoli, Naples, Italy.
  • UNESCO Chair for Health Education and Sustainable Development, University Federico II, Naples, Italy.

Zitieren

APA

Pivonello, R., Simeoli, C., Di Paola, N., Larocca, A., Crescenzo, E. M., & Colao, A. (2024). Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing’s Syndrome. touchREVIEWS in Endocrinology, 20(1). https://doi.org/10.17925/ee.2024.20.1.8

Vancouver

Pivonello R, Simeoli C, Di Paola N, Larocca A, Crescenzo EM, Colao A. Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing’s Syndrome. touchREVIEWS in Endocrinology. 2024;20(1). doi:10.17925/ee.2024.20.1.8

BibTeX
@article{Pivonello2024,
  author = {Pivonello, Rosario and Simeoli, Chiara and Di Paola, Nicola and Larocca, Angelica and Crescenzo, Erminio Massimo and Colao, Annamaria},
  title = {Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing’s Syndrome},
  journal = {touchREVIEWS in Endocrinology},
  year = {2024},
  volume = {20},
  number = {1},
  doi = {10.17925/ee.2024.20.1.8}
}
Kostenlos starten →